BioPharma Terug naar discussie overzicht

CELGENE

1. [verwijderd] 29 december 2005 18:33

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Iemand bekend met dit bedrijf ?? www.celgene.com/
   koers vandaag bijna + 6%
   
   Volgens eigen site worden aandelen binnenkort (per 17 feb 2006) opgesplitst -->> "Two-For-One Stock Split"
   
   NASDAQ: CELG
   quotes.nasdaq.com/asp/summaryquote.as...
   
   Wellicht een aandeel om te volgen ??
   
   groetjes,
   De Oliemolen, Herman
2. [verwijderd] 29 december 2005 19:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Celgene Corporation
   
   CELGENE CORPORATION (NASDAQ:CELG)
   
   Share price now: $61.62
   Share price close: $57.48
   Change: 7.20%
   52 Wk.High: $63.27
   52 Wk.Low: $24.70
   
   Today December 28, 2005 Celgene Corporation share value is up after yesterdays FDA approval of a drug to treat anemia in people who suffer from certain kinds of rare bone marrow disorders known as myelodyplastic syndromes, or MDS. Celgene Corp. plans to market the drug lenalidomide, as Revlimid.
   MDS refers to various disorders caused when bone marrow does not make enough normal blood cells. Patients with MDS can require blood and platelet transfusions and treatment with antibiotics for infections. Patients treated with Revlimid in clinical trials went transfusion-free for 44 weeks on average, according to the FDA. About 7,000 to 12,000 new cases of MDS are diagnosed each year in the United States. Symptoms include weakness, fatigue, infections, bruising, bleeding and fever.
   "This new product will offer a much needed treatment option for patients suffering from this rare illness that, in some cases, has been found to progress to fatal forms of leukemia," said Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research.
   The drug is similar to thalidomide, known to cause birth defects.
   The company must market Revlimid under a risk management plan to keep it from being used by women who may become pregnant. Female patients must undergo pregnancy testing and give informed consent before they can take the drug, which will bear a so-called "black box warning" on its label. Pharmacists and others who prescribe and dispense the drug must register with the risk management program, the FDA said.
   The warning also includes the potential need to lower the common dose due to suppressed blood counts and increased risk of blood clots in patients, the FDA said. Common side effects of Revlimid include low platelet count, low white blood cell count, diarrhea, itch, rash and fatigue.
   Celgene Corporation engages in the discovery, development, and commercialization of therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic, and proteomic targets. Its lead product, THALOMID, is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The company, through a supply and distribution agreement, with GlaxoSmithKline, distributes ALKERAN, a therapy for the palliative treatment of multiple myeloma and for palliation of carcinoma of the ovary. Its RITALIN family of drugs includes Focalin (d-MPH), which is used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder in school-age children. The company has various products in the preclinical and clinical-stage, including immunomodulatory drugs and selective cytokine inhibitory drugs. Celgene also produces compounds such as Benzopyrans and Selective Estrogen Receptor Modulators, Kinases Inhibitors, Tubulin Inhibitors, and Ligase Modulators. The company has collaborative agreements with Novartis Pharma AG; and strategic partnership agreements with Pharmion Corporation, Penn Pharmaceuticals Services Limited, and GlaxoSmithKline. The company markets and sells its products in the United States and Canada primarily through wholesale distributors. Celgene was organized in 1980 as a unit of Celanese Corporation and was spun-off in 1986. The company is headquartered in Warren, New Jersey.
   
   Written by
   Geraldine Mebesius
   
   Geraldine Mebesius and The Bellwether report do not have a vested interest in any of the above companies.
3. [verwijderd] 30 maart 2006 14:58

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   koers 29 maart van $ 41,35 naar $ 43,28 -> stijging dus 4,67%
   
   koers 30/12/2005 -> $ 64,80
   
   koers 29/03/2006 -> $ 43,28 -> na splitsing dus !
   
   stijging t.o.v. 30/12/2005 ---> 33,6%
   
   groetjes,
   De Oliemolen - Herman
4. [verwijderd] 12 juli 2006 17:45

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   aossa schreef:

   Gevonden op het yahoo-DNA-forum
   
   "The Next Big Biotech Winner"...Celgene (CELG).
   skylinetools.com/ee/CELG_125REASONS.doc
   
   

   post van aossa op het Crucell forum
   
   groetjes,
   De Oliemolen - Herman